---
title: "This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293338058.md"
description: "Top Wall Street analysts initiated coverage on five stocks with bullish outlooks. BMO Capital's Connor Mackay rated Insmed (INSM) Outperform with a $192 price target, while Malcolm Hoffman rated Axsome Therapeutics (AXSM) Outperform with a $310 target. Compass Point's Rob Simone gave American Healthcare REIT (AHR) a Buy rating at $70. BMO's Connor Murphy rated Trevi Therapeutics (TRVI) Outperform at $36, and Rodman & Renshaw's Seema Sheoran rated Eledon Pharmaceuticals (ELDN) Buy at $12."
datetime: "2026-07-21T11:58:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293338058.md)
  - [en](https://longbridge.com/en/news/293338058.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293338058.md)
---

# This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   BMO Capital analyst Connor Mackay initiated coverage on **Insmed Inc** (NASDAQ:INSM) with an Outperform rating and announced a price target of $192. Insmed shares closed at $107.02 on Monday. See how other analysts view this stock.
-   BMO Capital analyst Malcolm Hoffman initiated coverage on **Axsome Therapeutics Inc** (NASDAQ:AXSM) with an Outperform rating and announced a price target of $310. Axsome Therapeutics shares closed at $221.64 on Monday. See how other analysts view this stock.
-   Compass Point analyst Rob Simone initiated coverage on **American Healthcare REIT Inc** (NYSE:AHR) with a Buy rating and announced a price target of $70. American Healthcare shares closed at $56.66 on Monday. See how other analysts view this stock.
-   BMO Capital analyst Connor Murphy initiated coverage on **Trevi Therapeutics Inc** (NASDAQ:TRVI) with an Outperform rating and announced a price target of $36. Trevi Therapeutics shares closed at $16.77 on Tuesday. See how other analysts view this stock.
-   Rodman & Renshaw analyst Seema Sheoran initiated coverage on **Eledon Pharmaceuticals Inc** (NASDAQ:ELDN) with a Buy rating and announced a price target of $12. Eledon Pharmaceuticals shares closed at $3.86 on Monday. See how other analysts view this stock.

Considering buying INSM stock? Here’s what analysts think:

_Photo via Shutterstock_

### Related Stocks

- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [AXSM.US](https://longbridge.com/en/quote/AXSM.US.md)
- [AHR.US](https://longbridge.com/en/quote/AHR.US.md)

## Related News & Research

- [Healthcare of Ontario Pension Plan Trust Fund Invests $16.49 Million in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/294039544.md)
- [FDA Acceptance of AXS-12 NDA for Narcolepsy Might Change The Case For Investing In Axsome (AXSM)](https://longbridge.com/en/news/293863080.md)
- [This Analyst Just Cut Its Price Target on SNDK Stock. Here's Why.](https://longbridge.com/en/news/293654906.md)
- [Illinois Municipal Retirement Fund Invests $884,000 in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/293726954.md)
- [Insmed Chair and CEO William Lewis disposes of 10,700 common shares worth $1.14 million](https://longbridge.com/en/news/293797688.md)